Calmare Therapeutics Stock Price To Earning
Calmare Therapeutics fundamentals help investors to digest information that contributes to Calmare Therapeutics' financial success or failures. It also enables traders to predict the movement of Calmare Stock. The fundamental analysis module provides a way to measure Calmare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calmare Therapeutics stock.
Calmare |
Calmare Therapeutics Company Price To Earning Analysis
Calmare Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Calmare Therapeutics Price To Earning | (0.68) X |
Most of Calmare Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calmare Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Calmare Therapeutics has a Price To Earning of -0.68 times. This is 102.63% lower than that of the Health Care Equipment & Supplies sector and 100.97% lower than that of the Health Care industry. The price to earning for all United States stocks is 102.37% higher than that of the company.
Calmare Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calmare Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calmare Therapeutics could also be used in its relative valuation, which is a method of valuing Calmare Therapeutics by comparing valuation metrics of similar companies.Calmare Therapeutics is currently under evaluation in price to earning category among its peers.
Calmare Fundamentals
| Return On Asset | -0.38 | |||
| Operating Margin | (2.14) % | |||
| Current Valuation | 11.54 M | |||
| Shares Outstanding | 30.38 M | |||
| Shares Owned By Institutions | 6.92 % | |||
| Number Of Shares Shorted | 212.63 K | |||
| Price To Earning | (0.68) X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 1.17 M | |||
| Gross Profit | 771.48 K | |||
| EBITDA | (2.43 M) | |||
| Net Income | (3.83 M) | |||
| Cash And Equivalents | 12.55 K | |||
| Current Ratio | 0.22 X | |||
| Book Value Per Share | (0.48) X | |||
| Cash Flow From Operations | (1.24 M) | |||
| Short Ratio | 3.99 X | |||
| Earnings Per Share | (0.13) X | |||
| Target Price | 0.79 | |||
| Beta | 0.57 | |||
| Market Capitalization | 11.09 K | |||
| Total Asset | 3.88 M | |||
| Retained Earnings | (62.01 M) | |||
| Working Capital | (12.68 M) | |||
| Current Asset | 3.96 M | |||
| Current Liabilities | 16.64 M | |||
| Z Score | -24.6 | |||
| Net Asset | 3.88 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Calmare Stock
If you are still planning to invest in Calmare Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calmare Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |